((自动化翻译由路透提供，请见免责声明 )) (更新)
11月12日 - ** 生物技术公司Novavax的 股价下跌12.4%，创下7.89美元的逾六个月新低；早盘下跌6.2%。
** 公司将其 COVID-19 疫苗 (link) 的 2024 年收入预期从早先预期的 2.75 亿美元至 3.75 亿美元下调至 1.75 亿美元至 2.25 亿美元。
** 第三季度，COVID疫苗的销售额为3820万美元，而预期为2900万美元。根据 LSEG编制的数据 ，第三季度 COVID 疫苗的 销售额为 3820 万美元，预计为 2900 万美元。
** COVID 疫苗是 Novavax 唯一上市的产品
** 公司报告第三季度净亏损 1.21 亿美元，预计亏损 1.33 亿美元
** 年初至今，股价上涨 78.7
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.